Editorial: Incorporating Phase 0 microdosing as a powerful tool into a new vision of drug development.
| Autor: | Weiss HM; Novartis Biomedical Research, Inc., Basel, Switzerland., Sugiyama Y; iHuman Institute, Shanghai Tech University, Shanghai, China.; Laboratory of Quantitative System Pharmacokinetics, Pharmacodynamics, Josai International University (JIU), Tokyo, Japan., van Duijn E; The Netherlands Organization for Applied Scientific Research, The Hague, Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in pharmacology [Front Pharmacol] 2024 Jul 16; Vol. 15, pp. 1455643. Date of Electronic Publication: 2024 Jul 16 (Print Publication: 2024). |
| DOI: | 10.3389/fphar.2024.1455643 |
| Abstrakt: | Competing Interests: Author HW was employed by Novartis Biomedical Research, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|